Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15477MR)

This product GTTS-WQ15477MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15477MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11308MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ528MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ10311MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ14276MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ7388MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ14163MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ14998MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ14142MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW